Literature DB >> 10206286

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma.

R Hoffmann1, A Franzke, J Buer, S Sel, K Oevermann, A Duensing, M Probst, S Duensing, H Kirchner, A Ganser, J Atzpodien.   

Abstract

The purpose of the study was to determine prognostic significance of pretreatment serum levels of different molecules involved in cell to cell interactions along with other clinical parameters in patients with metastatic renal cell carcinoma. sICAM-1, sVCAM-1 and sELAM-1 serum levels were determined by ELISA assays in sera from 99 patients with histologically confirmed progressive metastatic renal cell carcinoma prior to initiation of systemic therapy. Kaplan-Meier survival analysis, log-rank statistics and two-proportional Cox regression analyses were employed to identify risk factors and to demonstrate statistical independence. In univariate analyses, the following pretreatment risk factors could be identified: serum sICAM-1 level > 360 ng ml(-1), erythrocyte sedimentation rate > 70 mm h(-1), serum C-reactive protein level > 8 mg l(-1), serum lactic dehydrogenase level > 240 U/l and neutrophil count > 6000 microl(-1). Multivariate analyses demonstrated statistical independence for serum sICAM-1 level, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level as pretreatment predictors of overall patient survival. The prognostic significance of sICAM-1 might indicate a role of this molecule for tumour progression, potentially in association with the abrogation of anti-tumour immune responses. The possibility of defining a pretreatment risk model based on sICAM-1 level, ESR and CRP also warrants further investigation, with regard to a possible linkage between acute phase proteins and sICAM-1 levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206286      PMCID: PMC2362808          DOI: 10.1038/sj.bjc.6690277

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  A form of circulating ICAM-1 in human serum.

Authors:  R Rothlein; E A Mainolfi; M Czajkowski; S D Marlin
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

2.  Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1.

Authors:  C A Welder; D H Lee; F Takei
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

3.  Inhibition of intercellular adhesion molecule 1-dependent biological activities by a synthetic peptide analog.

Authors:  J V Fecondo; S B Kent; A W Boyd
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity.

Authors:  M W Makgoba; M E Sanders; G E Ginther Luce; E A Gugel; M L Dustin; T A Springer; S Shaw
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

5.  Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders.

Authors:  M Maio; A Pinto; A Carbone; V Zagonel; A Gloghini; G Marotta; D Cirillo; A Colombatti; F Ferrara; L Del Vecchio
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

6.  Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction.

Authors:  J C Becker; C Termeer; R E Schmidt; E B Bröcker
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

7.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions.

Authors:  P Natali; M R Nicotra; R Cavaliere; A Bigotti; G Romano; M Temponi; S Ferrone
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

8.  Force contribution of the LFA-1/ICAM-1 complex to T cell adhesion.

Authors:  K L Sung; P Kuhlman; F Maldonado; B A Lollo; S Chien; A A Brian
Journal:  J Cell Sci       Date:  1992-09       Impact factor: 5.285

9.  Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.

Authors:  N K Foreman; D R Rill; E Coustan-Smith; E C Douglass; M K Brenner
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1.

Authors:  V T Moy; A A Brian
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  9 in total

1.  Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.

Authors:  P Royston; W Sauerbrei; A Ritchie
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

2.  An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma.

Authors:  P Royston; M Reitz; J Atzpodien
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

3.  Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.

Authors:  U M Vogl; H Zehetgruber; M Dominkus; M Hejna; C C Zielinski; A Haitel; M Schmidinger
Journal:  Br J Cancer       Date:  2006-08-29       Impact factor: 7.640

Review 4.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Metastatic renal carcinoma comprehensive prognostic system.

Authors:  J Atzpodien; P Royston; T Wandert; M Reitz
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

6.  Preoperative Erythrocyte Sedimentation Rate Independently Predicts Overall Survival in Localized Renal Cell Carcinoma following Radical Nephrectomy.

Authors:  Brian W Cross; Timothy V Johnson; Austin B Derosa; Kenneth Ogan; John G Pattaras; Peter T Nieh; Omer Kucuk; Wayne B Harris; Viraj A Master
Journal:  Int J Surg Oncol       Date:  2012-07-29

Review 7.  Novel concepts in the staging of renal cell carcinoma.

Authors:  Dan Leibovici; Arie Lindner; Avishay Sella; Amnon Zisman
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

8.  Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.

Authors:  Henry Adekola; Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Zhong Dong; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-10-28

9.  Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma.

Authors:  Yue Wang; Gaoxiang Li; Fangning Wan; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.